634 related articles for article (PubMed ID: 17312304)
21. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review.
Iqbal J; Ginsburg OM; Wijeratne TD; Howell A; Evans G; Sestak I; Narod SA
Cancer Treat Rev; 2012 Jun; 38(4):318-28. PubMed ID: 21775065
[TBL] [Abstract][Full Text] [Related]
22. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
[TBL] [Abstract][Full Text] [Related]
23. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
Fisher B; Costantino JP; Wickerham DL; Redmond CK; Kavanah M; Cronin WM; Vogel V; Robidoux A; Dimitrov N; Atkins J; Daly M; Wieand S; Tan-Chiu E; Ford L; Wolmark N
J Natl Cancer Inst; 1998 Sep; 90(18):1371-88. PubMed ID: 9747868
[TBL] [Abstract][Full Text] [Related]
24. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
Martino S; Cauley JA; Barrett-Connor E; Powles TJ; Mershon J; Disch D; Secrest RJ; Cummings SR;
J Natl Cancer Inst; 2004 Dec; 96(23):1751-61. PubMed ID: 15572757
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
[TBL] [Abstract][Full Text] [Related]
26. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.
Gail MH; Costantino JP; Bryant J; Croyle R; Freedman L; Helzlsouer K; Vogel V
J Natl Cancer Inst; 1999 Nov; 91(21):1829-46. PubMed ID: 10547390
[TBL] [Abstract][Full Text] [Related]
27. Overview of the main outcomes in breast-cancer prevention trials.
Cuzick J; Powles T; Veronesi U; Forbes J; Edwards R; Ashley S; Boyle P
Lancet; 2003 Jan; 361(9354):296-300. PubMed ID: 12559863
[TBL] [Abstract][Full Text] [Related]
28. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group.
Holli K; Valavaara R; Blanco G; Kataja V; Hietanen P; Flander M; Pukkala E; Joensuu H
J Clin Oncol; 2000 Oct; 18(20):3487-94. PubMed ID: 11032589
[TBL] [Abstract][Full Text] [Related]
30. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
[TBL] [Abstract][Full Text] [Related]
31. Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study.
Bertelsen L; Bernstein L; Olsen JH; Mellemkjaer L; Haile RW; Lynch CF; Malone KE; Anton-Culver H; Christensen J; Langholz B; Thomas DC; Begg CB; Capanu M; Ejlertsen B; Stovall M; Boice JD; Shore RE; ; Bernstein JL
J Natl Cancer Inst; 2008 Jan; 100(1):32-40. PubMed ID: 18159070
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer.
Shen Y; Costantino JP; Qin J
J Natl Cancer Inst; 2008 Oct; 100(20):1448-53. PubMed ID: 18840821
[TBL] [Abstract][Full Text] [Related]
33. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.
Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM
J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536
[TBL] [Abstract][Full Text] [Related]
34. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
Belfiglio M; Valentini M; Pellegrini F; De Berardis G; Franciosi M; Rossi MC; Sacco M; Nicolucci A;
Cancer; 2005 Dec; 104(11):2334-9. PubMed ID: 16245354
[TBL] [Abstract][Full Text] [Related]
35. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
Coombes RC; Hall E; Gibson LJ; Paridaens R; Jassem J; Delozier T; Jones SE; Alvarez I; Bertelli G; Ortmann O; Coates AS; Bajetta E; Dodwell D; Coleman RE; Fallowfield LJ; Mickiewicz E; Andersen J; Lønning PE; Cocconi G; Stewart A; Stuart N; Snowdon CF; Carpentieri M; Massimini G; Bliss JM; van de Velde C;
N Engl J Med; 2004 Mar; 350(11):1081-92. PubMed ID: 15014181
[TBL] [Abstract][Full Text] [Related]
37. [The interruption of a study following an "ad interim" analysis. The example of the NSABP-P1 study].
Savarese A
Suppl Tumori; 2004; 3(4):S23-4. PubMed ID: 15206204
[No Abstract] [Full Text] [Related]
38. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.
Reis SE; Costantino JP; Wickerham DL; Tan-Chiu E; Wang J; Kavanah M
J Natl Cancer Inst; 2001 Jan; 93(1):16-21. PubMed ID: 11136837
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
; Rudenstam CM; Zahrieh D; Forbes JF; Crivellari D; Holmberg SB; Rey P; Dent D; Campbell I; Bernhard J; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gelber RD; Coates AS
J Clin Oncol; 2006 Jan; 24(3):337-44. PubMed ID: 16344321
[TBL] [Abstract][Full Text] [Related]
40. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
Smith SG; Sestak I; Howell A; Forbes J; Cuzick J
J Clin Oncol; 2017 Aug; 35(23):2666-2673. PubMed ID: 28661758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]